SCHEMBL6582182

SCHEMBL6582182

C#CCN(Cc1cc2c(=O)n(C)c(CN3CCC(O)CC3)nc2cc1Cl)c1ccc(C(=O)O)cc1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 19/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790569 0.92 NAMPT (0.66) NAMPT
SCHEMBL6580507 0.92 NAMPT (0.65) NAMPT
SCHEMBL6583938 0.92 NAMPT (0.67) NAMPT
SCHEMBL6902914 0.92 NAMPT (0.73) NAMPT
SCHEMBL6583098 0.90 NAMPT (0.66) NAMPT
SCHEMBL6582292 0.90 NAMPT (0.64) NAMPT
SCHEMBL6582863 0.90 NAMPT (0.59) NAMPT
SCHEMBL6581576 0.88 NAMPT (0.65) NAMPT
SCHEMBL6580435 0.86 NAMPT (0.71) NAMPT
SCHEMBL6580446 0.85 NAMPT (0.55) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1155012-B1 ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES CANCER REC TECH LTD (GB) 2004-04-14 EP disclosed
US-6699861-B1 ANTI-CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-03-02 US disclosed